Preventive treatment with the antibiotic levofloxacin can lower the incidence of fever and death in people newly diagnosed with multiple myeloma, results from a…
News
A recent partnership between Indapta Therapeutics and Lonza is advancing the development of an off-the-shelf cell therapy designed to treat multiple types of cancers, including…
The European Medicines Agency has agreed to review the application of  GlaxoSmithKline‘s belantamab mafodotin for the treatment of heavily treated multiple myeloma patients, the company…
Takeda and Snow Companies won one of the top prizes in PM360’s annual Pharma Choice Awards for an app aimed at…
Researchers are continuing to study how the combination of Oncolytics Biotech‘s virus-based anti-cancer therapy Reolysin (pelareorep) and Kyprolis (carfilzomib) provides benefits…
Allogene Therapeutics and SpringWorks Therapeutics have launched a clinical trial collaboration to conduct a Phase…
MYELOMA
Sanofi Partners to Develop Diagnostic Test for Multiple Myeloma Patients on Potential Therapy
Sanofi announced that it partnered with Sebia to develop a new multiple myeloma diagnostic test that will help to mitigate the interference of isatuximab…
The U.S. Food and Drug Administration (FDA) has granted priority review status to GlaxoSmithKline‘s application seeking the approval of belantamab mafodotin for the treatment of heavily…
The European Commission has approved Darzalex (daratumumab), in combination with standard pre-transplant therapy, to treat newly diagnosed multiple myeloma patients who are…
NexImmune will soon initiate a Phase 1/2 trial evaluating its cell therapy NEXI-002 in people with multiple myeloma who failed three or…
Recent Posts
- When the caregiver role starts to feel like a second skin
- Developer seeks US approval of next-gen med for hard-to-treat myeloma
- Upping early detection is goal this Pancreatic Cancer Awareness Month
- My husband and I aren’t just each other’s caregivers; we’re care partners
- Under-the-skin myeloma therapy shows strong responses in Phase 2 trial